SCHEMBL15054566

SCHEMBL15054566

Cc1cnc(CO)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ KDM4E B2RXH2 4/20 0.41
▸ ATM Q13315 1/20 0.37
▸ SELL P14151 1/20 0.37
▸ SELP P16109 1/20 0.37
▸ SELE P16581 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.36
▸ CCR1 P32246 1/20 0.35
▸ CCR5 P51681 1/20 0.35
▸ CCR8 P51685 1/20 0.35
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ TRPA1 O75762 1/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ DPP4 P27487 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24925495 0.83 KDM4E (0.40) ALDH1A1KDM4ESELLSELPSELE
SCHEMBL31168484 0.80 GCK (0.36) KDM4ESELLSELPSELEACHE
SCHEMBL1758493 0.80 NOS3 (0.46) ALDH1A1KDM4EATMACHEHCAR2
SCHEMBL7883634 0.77 ALDH1A1 (0.45) ALDH1A1L3MBTL1KDM4EACHEDPP4
SCHEMBL31527644 0.77 CCR1 (0.34) ALDH1A1L3MBTL1KDM4EATMHCAR2
SCHEMBL17173719 0.77 CCR1 (0.34) ALDH1A1KDM4EATMCCR1CCR5
SCHEMBL16741027 0.77 AGBL2 (0.37) ALDH1A1KDM4EATMHCAR2CCR1
SCHEMBL15034187 0.75 DPP4 (0.45) ALDH1A1L3MBTL1ATMACHEHPGD
SCHEMBL18911298 0.74 ALDH1A1 (0.42) ALDH1A1L3MBTL1KDM4EHPGDHSD17B10
SCHEMBL31168612 0.74 KDM4E (0.41) ALDH1A1KDM4EATMHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2021-07-22 — — US disclosed
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2021-04-27 — — US disclosed
EP-3424904-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-12-02 — — EP disclosed
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2020-07-09 — — US disclosed
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2019-08-27 — — US disclosed
EP-3424904-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE Allergan, Inc. (US) 2019-01-09 — — EP disclosed
EP-2794561-B1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-08-22 — — EP disclosed
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-05-18 — — US disclosed
US-9567328-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2017-02-14 — — US disclosed
EP-2794561-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2014-10-29 — — EP disclosed
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-07-18 — — US disclosed
WO-2013096496-A2 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216440-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885
US-20210221810-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885
US-10392382-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885
US-10988474-B2 Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885
US-20130184463-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885
US-20170137423-A1 COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, PTGER2 ALDH1A1 2051/4885L3MBTL1 3474/4885KDM4E 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback